HealthPartners Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, HealthPartners Institute sits in the top decile of US sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count).
HealthPartners Institute: 146 sponsored US clinical trials, 12 recruiting.
HealthPartners Institute sponsors 146 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 111 completed. 11 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes, with 3 trials.
Top-decile sponsor footprint
HealthPartners Institute ranks in the top decile of sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
111 of 126 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
146 total, page 3 of 3
Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns
NCT01390636
Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix Definition
NCT01390610
The Impact of Food on Blood Sugar in People With Type 2 Diabetes
NCT01237314
Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes
NCT01237301
Simulated Diabetes Training for Resident Physicians
NCT00979823
Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia
NCT01184014
Healthy Homes/Healthy Kids Preschool
NCT01080885
Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes
NCT01170208
Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine
NCT01089569
Characteristics of Persons With an Eating Disorder and Type 1 Diabetes
NCT00945711
Healthy Homes/Healthy Kids_5-9
NCT01084590
Personalized Physician Learning to Improve Hypertension Care
NCT00903071
Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring
NCT01072565
Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors
NCT01074320
Computer-Assisted Tobacco Interventions in Dental Offices
NCT01584882
Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes
NCT00993824
Home Blood Pressure Telemonitoring and Case Management to Control Hypertension
NCT00781365
Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.
NCT00948311
Passport to Brain Wellness in Sedentary Adults
NCT00979446
Barriers to the Implementation of Complete Insulin Order Sets
NCT00813280
Prospective Randomized Clinical Trial Evaluating the Impact of Vinegar on High Density Lipoprotein
NCT00755924
Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control
NCT00806520
Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder
NCT00818142
Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food
NCT00818077
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
NCT00466232
The Balance Study Balancing Life and Reducing Stress For Those Providing Elder Care
NCT00615082
L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
NCT00754767
Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide
NCT00569907
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide
NCT00803920
Assessment of Non-Fasting vs. Fasting Lipid Measures in Diabetes Patients
NCT00569959
Keep It Off: A Weight Loss Maintenance Study
NCT00702455
Impact of Continuing Medical Education (CME) Insulin Program
NCT00824603
Establishing Ambulatory Glucose Profiles for People Without Diabetes Using CGM Data
NCT00467675
Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes
NCT00805506
Reducing Clinical Inertia in Diabetes Care
NCT00272402
Develop Novel Methods to Display, Report and Analyze CGM Data for Clinical Decision-Making in People With Diabetes
NCT00465881
Telephone Counseling for Snuff Users
NCT00265681
Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes
NCT00202033
Examining Psychosocial Mediators of Exercise Behavior
NCT00142688
Pilot Study of BOTOX for Migraine Headaches
NCT00850421
Admission Glucose ICU Study
NCT00569322
Activity, Rheumatoid and Osteoarthritis, and Weight Management
NCT00365404
Keep Active Minnesota
NCT00283452
Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
NCT00202059
Predictors of Lymphedema Following Breast Cancer Surgery
NCT00202046
SimCare: Physician Intervention to Improve Diabetes Care
NCT00262704
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 12 |
| Phase 3 | 1 |
| Phase 4 | 10 |
What is open in the HealthPartners Institute pipeline
12 recruiting of 146 indexed (8% open); 111 completed (76%).
Phase mix: 11 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: Type 2 Diabetes (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
HealthPartners Institute: open-pipeline peers nationwide
Peers matched on 146 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
HealthPartners Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 146 trials (± recruiting share)
- Mylan Pharmaceuticals · 146 trials · 1% recruiting
- SCRI Development Innovations · 146 trials · 3% recruiting
- Forest Laboratories · 145 trials · 0% recruiting
- National Institute of Environmental Health Sciences (NIEHS) · 145 trials · 10% recruiting
Sponsors near 8% open enrollment (± trial volume)
- National Eye Institute (NEI) · 8% recruiting · 221 trials
- Acrotech Biopharma · 8% recruiting · 24 trials
- Atlanta VA Medical Center · 8% recruiting · 12 trials
- Beacon Therapeutics · 8% recruiting · 12 trials
Related
What to do with this HealthPartners Institute page
146 registered trials is a research-attention snapshot, not an endorsement of HealthPartners Institute or any single study.
- 12 of HealthPartners Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Type 2 Diabetes is the condition HealthPartners Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
HealthPartners Institute pipeline card: 146 registered trials from official public datasets.Report a data error.